Results 201 to 210 of about 88,910 (264)

Adverse drug reactions induced by antihypertensive agents [PDF]

, 2020
Reshma Elizabeth Raju, Arshi Hanif
openalex  

Clinical risk phenotypes in diabetes and their associations with adverse cardiovascular events: A report from the Silesia Diabetes‐Heart Project

Diabetic Medicine, EarlyView.
Abstract Aims Diabetes is characterized by clinical heterogeneity. This study aimed to identify different clinical phenotypes of real‐world people with diabetes and to assess their associations with major adverse cardiovascular events (MACEs). Methods From a prospective Polish registry of people with diabetes, hierarchical cluster analysis was ...
Marta Mantovani, Hanna Kwiendacz, Krzysztof Irlik, Tommaso Bucci, Mirela Hendel, Steven H. M. Lam, Bi Huang, Paulina Szromek‐Białek, Monika Niezgoda, Uazman Alam, Giuseppe Boriani, Janusz Gumprecht, Gregory Y. H. Lip, Katarzyna Nabrdalik   +13 more
wiley   +1 more source

Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study. [PDF]

Front Pharmacol
Du K, Li A, Zhang CY, Li SM, Chen P.
europepmc   +1 more source

Treatment of hypertensive patients with mebutamate, a new antihypertensive drug. A preliminary study.

, 1962
John L. S. Holloman
openalex   +2 more sources

Eplerenone improves kidney function and cardiac performance in obese male mice

Diabetic Medicine, EarlyView.
Abstract Aims Renin‐angiotensin‐aldosterone system (RAAS) activation mediates obesity‐associated cardiorenal dysfunction. Due to an incomplete understanding of the molecular mechanisms, the clinical use of RAAS antagonism in obesity‐associated cardiometabolic complications remains uncertain.
Ayman K. Banah, Bingxue Qi, Ryan Koh, Alexander Lawlor, Tianzhen Wang, Vishal Musale, Joanne Mains, Colin E. Murdoch, Li Kang   +8 more
wiley   +1 more source

Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study. [PDF]

BMJ Open
Tomas A, Wettermark B, Nyberg F, Hajiebrahimi M.   +3 more
europepmc   +1 more source

Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort

Diabetic Medicine, EarlyView.
Abstract Aims This study assesses national trends and, socio‐demographic and clinical factors associated with polypharmacy and potentially in appropriate prescribing among people with type 2 diabetes in Scotland from 2012 to 2022. Methods Retrospective cohort study using nationwide data from the Scottish Care Information – Diabetes database ...
William Berthon, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Amanda de Assuncao Santiago Fernandes, Lauren E. Walker, Rory J. McCrimmon, Helen M. Colhoun, David A. McAllister, Peter Hanlon   +8 more
wiley   +1 more source

Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data. [PDF]

Eur Heart J Cardiovasc Pharmacother
Nie H, Zhao W, Wang Q, Zhou W.
europepmc   +1 more source

A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Antipsychotics increase metabolic syndrome (MetSyn) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine‐associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Edward Jackson, Kenneth Koblan, Seth C. Hopkins   +11 more
wiley   +1 more source

The causal relationship between antihypertensive drugs and depression: a Mendelian randomization study of drug targets. [PDF]

Front Endocrinol (Lausanne)
Yang Z, Li J, Huang P, Li Z, He J, Cai D, Lai Y.   +6 more
europepmc   +1 more source